Table 1 Patients’ characteristics
Early disease (16 patients) | Metastatic disease (24 patients) | ||
|---|---|---|---|
Age, yr, median (range) | 53 (33–77) | Age, yr, median (range) | 58 (39–70) |
No. (%) | No. (%) | ||
Menopausal status | Menopausal status | ||
Premenopausal | 4 (25%) | Premenopausal | 7 (29.2%) |
Postmenopausal | 10 (62.5%) | Postmenopausal | 14 (58.3%) |
Unknown | 2 (12.5%) | Unknown | 3 (12.5%) |
Tumor size | Tumor size | ||
pT1 | 9 (56.3%) | pT1 | 4 (16.7%) |
pT2 | 5 (31.3%) | pT2 | 12 (50%) |
pT3 | 0 (0%) | pT3 | 4 (16.7%) |
Unknown | 2 (12.5%) | Unknown | 4 (16.7%) |
Lymph node status | Lymph node status | ||
Node-negative | 4 (25%) | Node-negative | 9 (37.5%) |
Node-positive | 11 (68.8%) | Node-positive | 10 (41.7%) |
Unknown | 1 (6.3%) | Unknown | 5 (20.8%) |
Histologic grade | Histologic grade | ||
Grade 1 | 0 (0%) | Grade 1 | 0 (0%) |
Grade 2 | 10 (62.5%) | Grade 2 | 12 (50%) |
Grade 3 | 3 (18.8%) | Grade 3 | 9 (37.5%) |
Grade 4 | Grade 4 | 3 (12.5%) | |
Unknown | 3 (18.8%) | Unknown | 0 (0%) |
Histologic subtype | Histologic subtype | ||
Ductal | 12 (75%) | Ductal | 17 (70.8) |
Lobular | 1 (6.3%) | Lobular | 2 (8.3%) |
Other | 3 (18.8%) | Other | 5 (20.8%) |
ER/PR tumor status | ER/PR tumor status | ||
Positive | 12 (75%) | Positive | 15 (62.5%) |
Negative | 2 (12.5%) | Negative | 6 (25%) |
Unknown | 2 (12.5%) | Unknown | 3 (12.5%) |
HER2 tumor status | HER2 tumor status | ||
Positivea | 7 (43.8%) | Positivea | 3 (12.5%) |
Negative | 6 (37.5%) | Negative | 18 (75%) |
Unknown | 3 (18.8%) | Unknown | 3 (12.5%) |
HR+/HER2− | 5 (31.3%) | HR+/HER2− | 12 (50%) |
HR+/HER2+ | 6 (37.5%) | HR+/HER2+ | 3 (12.5%) |
HR−/HER2+ | 1 (6.3%) | HR−/HER2+ | 0 (0%) |
HR−/HER2− | 1 (6.3%) | HR−/HER2− | 6 (25%) |
Unknown combination | 3 (18.8%) | Unknown combination | 3 (12.5%) |
Disease sites | |||
1 | 8 (33.3%) | ||
2 | 11 (45.8%) | ||
≥ 3 | 4 (16.6%) | ||
Unknown | 1 (4.2%) | ||
Predominantly visceral disease | |||
Yes | 15 (62.5%) | ||
No | 7 (29.1%) | ||
Unknown | 2 (8.3%) | ||
Primary breast cancer | |||
Adjuvant | 16 (66.7%) | ||
Metastatic | 7 (29.2%) | ||
Unknown | 1 (4.2%) | ||
Line of treatment | |||
First | 8 (33.3%) | ||
Second | 8 (33.3%) | ||
Third | 3 (12.5%) | ||
Fourth or later | 5 (20.8%) | ||